Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

127 results about "Sinus inflammation" patented technology

Methods of measuring symptoms of chronic rhinosinusitis

InactiveUS20070226012A1Improvement in treatment of chronicAble to understandComputer-assisted medical data acquisitionSpecial data processing applicationsSigns and symptomsPatient population
A method for diagnosing, assessing, and determining of the efficacy of a treatment regimen for chronic rhinosinusitis is presented. The method comprises collecting subjective information from a patient or patient population in the form of patient entries into a daily diary, wherein the daily diary comprises the patient responses to questions directed to the presence or absence of a group of clinical signs and symptoms related to chronic rhinosinusitis. Based upon the patient responses in the daily diaries, certain of the clinical signs and symptoms are identified for use in the generation of a scoring tool useful in the determination and assessment of the efficacy of a treatment regimen for chronic rhinosinusitis, as well as in the clinical determination of the severity of the symptoms related to chronic rhinosinusitis.
Owner:NARYX PHARMA INC

Compositions comprising azelastine and methods of use thereof

The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and / or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also generally relates to pharmaceutical compositions comprising one or more active pharmaceutical ingredients, such as azelastine or pharmaceutically acceptable salts or esters thereof including azelastine hydrochloride, particularly wherein the compositions are provided in unit dosage form. In certain embodiments, the invention provides such unit dosage pharmaceutical compositions comprising azelastine hydrochloride formulated for use as nasal sprays and / or ocular solutions or drops. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of a variety of allergic and non-allergic conditions, particularly conjunctivitis, sinusitis, rhinitis and rhinosinusitis. The compositions and methods of the present invention provide significant value in terms of patient acceptability, convenience, and compliance.
Owner:MEDA PHARMA INC

Solvating system and sealant for medical use in the sinuses and nasal passages

ActiveUS20070264342A1Increased drug resistanceReduction and elimination in amountAntibacterial agentsPowder deliveryNasal passageBiofilm
Chronic rhinosinusitis and other bacterial sinus conditions may be treated by applying a solvating system containing a surfactant to a bacterial biofilm in a nasal or sinus cavity, disrupting the biofilm, and applying a protective layer of a polymeric film-forming medical sealant.
Owner:MEDTRONIC XOMED INC

Drug combinations containing pde4 inhibitors and nsaids

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma.The invention particularly relates to those drug combinations which, in addition to one or more, preferably one PDE4 inhibitor of general formula 1wherein X is SO or SO2, but preferably SO, and whereinR3 denotes an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryl and wherein R1 and R2 have the meanings given in claim 1, contain at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.
Owner:BOEHRINGER INGELHEIM INT GMBH

Formulations and methods for treating rhinosinusitis

The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.
Owner:MYLAN SPECIALTY

Indole Compound and Use Thereof

InactiveUS20080188532A1Increased airway hyperreactivityImprove respiratory functionBiocideSenses disorderDiseaseBronchial epithelium
The present invention relates to a compound represented by the formula (I),wherein all symbols are as defined in the description,a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and / or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.
Owner:ONO PHARMA CO LTD

Human thymus stromal lymphopoietin monoclonal antibody and application thereof

The invention relates to the technical field of antibodies, and especially relates to a human thymus stromal lymphopoietin monoclonal antibody and an application thereof. The TSLP antibody can be specifically combined with hTSLP, has high affinity, and can effectively inhibit the combination of TSLP and a receptor thereof so as to inhibit activation of a downstream signal path and activation of immune cells by TSLP. The TSLP antibody has great significance in detection of the content of hTSLP and allergic asthma, and diagnosis, treatment and prognosis of inflammatory or allergic inflammatory diseases such as chronic obstructive pulmonary disease, allergic dermatitis, allergic rhinitis, allergic nasosinusitis, eosinophilic granulocytic esophagitis, allergic conjunctivitis, inflammatory bowel disease or atopic dermatitis.
Owner:IPHASE THERAPEUTICS LTD

Combinations of medicaments, containing PDE4-inhibitors and EP4-receptor-antagonists

InactiveUS20130225609A1BiocideAntipyreticDiseaseCOPD
The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors (1) at least one EP4 receptor antagonist (2), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma.The invention relates in particular to those medicament combinations which contain, in addition to one or more, preferably one, PDE4 inhibitor of general formula 1wherein X is SO or SO2, but preferably SO, and whereinR1, R2, R3 and R4 have the meanings given in claim 1, at least one EP4 receptor antagonist (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.
Owner:BOEHRINGER INGELHEIM INT GMBH

Traditional Chinese medicine decoction for treating chronic paranasal sinusitis and preparation method thereof

The invention discloses a traditional Chinese medicine decoction for treating chronic paranasal sinusitis and a preparation method thereof. The traditional Chinese medicine decoction mainly consists of honeysuckle, platycodon grandiflorus, angelica dahurica, radix paeoniae rubra, lotus rhizome node, siberian cocklour fruit, divaricate saposhnikovia root, acorus gramineus, gardenia, liquorice, wrinkled gianthyssop herb, magnolia flower and mint. The traditional Chinese medicine composition has the effects of stopping pain and smoothening the nose, has the effect of well relieving various pain symptoms and stuffy noses and running noses caused by the chronic paranasal sinusitis and has the obvious effect of treating the chronic paranasal sinusitis.
Owner:井彦华

Traditional Chinese herbal preparation for treating chronic nasosinusitis

The invention discloses a traditional Chinese herbal preparation for treating chronic nasosinusitis, which consists of gypsum, honeysuckle, chrysanthemum, ligusticum wallichii, radix angelicae, mint, dried tangerine, figwort root, spina gleditsiae, radices sileris, radix rehmanniae, angelica sinensis, pollen, magnolia flower, Siberian cocklour fruit, platycodon grandiflorum, radix bupleuri, radixscutellariae, herba pogostemonis, radix puerariae, bighead atractylodes rhizome and liquorice, the medicines are composited to generate a synergistic effect of all the medicine efficacies, and the preparation has the effects of opening the inhibited lung-energy, dispelling pathogenic wind, clearing liver fire, cooling and activating blood, eliminating stagnation and discharging pus. The traditional Chinese herbal preparation adopts the pharmacological basis on treating chronic nasosinusitis that: by aiming at the etiological pathology of the chronic nasosinusitis, the traditional Chinese herbal preparation prevents bacteria, diminish inflammation, avoid allergic reaction, improve immunity of the organism and microcirculation, and promote tissue cell repair. The preparation of the invention not only is in accordance with the principle of medicine and health syndrome differentiation and treatment in China, but also is supported by modern pharmological study, so the curative effect is obvious; and the preparation has no toxic or side effect, stable long-term effect and convenience for taking, and is worth being popularized.
Owner:NANYANG MEDICAL COLLEGE

Nasal polymer gel filling material and preparation method thereof

The invention discloses a nasal polymer gel filling material and a preparation method thereof. The nasal polymer gel filling material is prepared from the following raw materials: gel and a crosslinking agent which is 0.1-2% of the mass of the gel. The preparation method comprises the following steps: adding the crosslinking agent to a water solution of gel to obtain a mixed solution; carrying out crosslinking reaction under the condition at 40-80 DEG C to obtain modified gel; soaking the modified gel into distilled water for 12-48 hours; replacing the water once at an interval of two hours; and carrying out freeze drying, so as to obtain the nasal polymer gel filling material. The gel filling material forms a compressed state when being placed, and is easy to put in, and light in adhesion with tissues, so that the expanded filling material is soft, and not easy to be extracted, and does not lead to adhesion of a nasal cavity. The inhibition ratio of the filling material on microorganisms such as staphylococcus aureus and escherichia coli can be up to over 90%, prevention of local infection is facilitated, and the anti-inflammatory action after chronic sinusitis-nasosinusitis surgery is improved.
Owner:深圳市博立生物材料有限公司

Injection containing pidotimod potassium salt and preparation method thereof

The invention discloses an injection containing a pidotimod potassium salt and a preparation method thereof. The preparation method comprises the following steps of: undergoing reaction between pidotimod and potassium hydroxide with equal mole in water or other solvent or a mixed solution of multiple solvents, preparing the pidotimod potassium salt and then preparing the injection. The injection containing the pidotimod potassium salt is characterized in that the effective component, the pidotimod, in the injection exists in the form of the pidotimod potassium salt, thus the solubility and the stability of the pidotimod in normal pH environment of a human body are improved. The injection containing the pidotimod potassium salt, disclosed by the invention, is used for treating the recurrent upper and lower respiratory tract infection (such as pharyngitis, tracheitis, bronchitis and tonsillitis), the recurrent infection (such as rhinitis, nasosinusitis and otitis), the urinary infection and gynecological infection, and can reduce the times of acute exacerbation, shorten the course of disease and relieve the degree of exacerbation; in addition, the injection can be also taken as the auxiliary treatment of antibiotics during the acute infection.
Owner:QINGDAO VLAND BIOTECH INC +1

Combinations of medicaments, containing PDE4-inhibitors and EP4-receptor- antagonists

InactiveUS20140350035A1BiocideAntipyreticDiseaseCOPD
The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors (1) at least one EP4 receptor antagonist (2), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma.The invention relates in particular to those medicament combinations which contain, in addition to one or more, preferably one, PDE4 inhibitor of general formula 1wherein X is SO or SO2, but preferably SO, and whereinR1, R2, R3 and R4 have the meanings given in claim 1, at least one EP4 receptor antagonist (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.
Owner:BOEHRINGER INGELHEIM INT GMBH

New treatment

ActiveUS20170112839A1Modulating CFTR activityDigestive systemRespiratory disorderSinusitisDisease
The invention provides a compound for use in treating or preventing a disease or condition selected from cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, mild pulmonary disease, bronchitis, bronchiectasis, idiopathic bronchiectasis, allergic bronchopulmonary aspergillosis, sinusitis, rhinosinusitis, CFTR-related metabolic syndrome (CRMS), pancreatitis, idiopathic chronic pancreatitis and Sjörgren's syndrome, or for use in preventing male infertility caused by congenital absence of the vas deferens, in a patient by modulating CFTR activity, which compound is 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof. The invention also provides a composition comprising (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (ii) a leukotriene receptor antagonist. The invention also provides a composition comprising (i) 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (ii) a CFTR potentiator or a CFTR corrector.
Owner:VERONA PHARMA

Methods and compositions for treating siglec-8 associated diseases

ActiveUS20170073413A1Diminished function of cellImpaired cell functionNervous disorderDigestive systemAsthmaAntibody
The invention provides methods and compositions for the prevention and treatment of Siglec-8 associated diseases such as chronic rhino sinusitis with concomitant asthma and aspirin-exacerbated respiratory disease. In particular, the invention provides methods for the prevention and treatment of Siglec-8 associated diseases through administration of antibodies or agonists that bind to human Siglec-8 or compositions comprising said antibodies or agonists. The invention also provides articles of manufacture or kits comprising antibodies or agonists that bind to human Siglec-8 for the prevention and treatment of Siglec-8 associated diseases such as chronic rhinosinusitis with concomitant asthma and aspirin-exacerbated respiratory disease.
Owner:ALLAKOS

Traditional Chinese medicine composition for treating acute sinusitis and preparation method thereof

The invention provides a traditional Chinese medicine composition for treating acute sinusitis and a preparation method thereof. The traditional Chinese medicine composition comprises an oral medicine and an external-use medicine. The oral medicine comprises the following raw materials: fortune eupatorium herb, Chinese angelica, biond magnolia flower, manchurian wildginger, long pepper, small centipeda herb, Siberian cocklour fruit, honeysuckle flower, suberect spatholobus stem, lilac pink herb, ginseng leaves, astragalus root, coptis, gentian root, lycium berry, pueraria root, arctium fruit, prunella spike, feather cockscomb seeds, radix liriopes, dendrobium, silybum marianum, rhizoma polygonati, radix acanthopanacis senticosi and licorice root; and the external-use medicine comprises the following raw materials: the biond magnolia flower, the manchurian wildginger, the long pepper, the small centipeda herb, the Siberian cocklour fruit, perilla leaves, mint, ephedra, lygodium spore, ligusticum root, Yuzhou uniflower swisscentaury root, achyranthes root, cowherb seeds, folium ilicis purpurea, radix bupleuri, cornu bubali, Japanese ampelopsis root, coptis, akebia fruit, tangerine peel, musk and the licorice root. The traditional Chinese medicine composition has the advantages that the efficiency for treating the acute sinusitis is high, the time of taking effect is faster, the pain of a patient can be quickly relieved within a short time, the cure rate is high, and the recurrence rate is low.
Owner:深圳市恒善堂医药有限公司

lomefloxacin aspartate compound

The present invention relates to a crystal form of lomefloxacin aspartate and a preparation method thereof. The present invention also relates to a pharmaceutical composition containing the above-mentioned crystal form of lomefloxacin aspartate and the crystal form is used to manufacture a treatment for Gram Human or animal respiratory tract infection, genitourinary system infection, gastrointestinal bacterial infection, abdominal cavity, biliary tract, typhoid and other infections, bone and joint infection, skin and soft tissue infection, sepsis and other systemic infection caused by positive or negative bacterial sensitive bacteria, Other infections, such as sinusitis, otitis media, blepharitis and other drugs.
Owner:TIANJIN HANKANG PHARMA BIOTECH

Herbal-based nasal solution and method of use thereof

A nasal solution and method for treating nasal and sinus inflammation. The nasal solution includes vitamin C, an extract of scutellaria radix, an extract of eleutherococcus radix, an extract of chamomile, and a pharmaceutically acceptable carrier which is suitable for administering the vitamin C, the scutellaria radix extract; the eleutherococcus radix extract; and the chamomile to the nose of a patient. The method includes administering the nasal solution which suppresses early phase and late phase mediators of allergic mucosal disease in order to maintain long-term inhibition of nasal and sinus inflammation.
Owner:ZNOVA

Medicinal composition for treating rhinitis

The invention discloses a medicinal composition, which comprises pharmaceutically effective dose of tolazoline hydrochloride, gentamycin sulfate, ribavirin, dexamethasone sodium phosphate, chlorphenamine maleate and a pharmaceutical carrier. The medicinal composition can be used for treating various acute or chronic rhinitis, sinusitis, purulent rhinitis, rhinitis sicca, atrophic rhinitis, allergic rhinitis and the like.
Owner:徐宏模

Use of rock inhibitors for promoting sinonasal epithelial cell repair

InactiveUS20200101056A1Antibacterial agentsOrganic active ingredientsDiseaseParanasal sinus mucosa
Novel methods and uses for promoting sinonasal epithelial cell repair in a subject are described. These methods and uses are based on the administration of Rho / ROCK signaling pathway inhibitors, such as ROCK inhibitors. Subjects that may benefit from these methods and uses are those suffering from diseases / conditions associated with impaired nasal and paranasal sinus mucosa integrity and / or defective sinonasal epithelial repair and regeneration, such as rhinosinusitis (e.g., chronic rhinosinusitis, CRS). The Rho / ROCK signaling pathway inhibitors may be used alone or in combination with other active agents, such as steroids and / or antibiotics.
Owner:VALERA FABIANA C P +5

Method for treating phthisis by inhaling atomized purple garlic liquid

The invention belongs to the technical field of medicine, and relates to a method for treating the phthisis and the respiratory disease by inhaling atomized purple garlic liquid, in particular to a method for treating the phthisis through the extracting solution of purple garlic (the purple garlic liquid) and an atomizer. The purple garlic liquid is extracted at the low temperature and is atomized by the atomizer into ultramicro particles with the diameter being about 0.2 micron, the atomized liquid can fully and evenly adhere to the pulmonary alveoli and the inner walls of the bronchi through the deep breathing and medicine feeding treatment, and due to the fact that the diameter of the atomized liquid is small, the atomized liquid permeates evenly and can reach the focal zone to carry out sterilization and take part in the lung blood microcirculation, and the active ingredient allisatin of the garlic liquid is conveyed along with the blood to kill and restrain bacteria. The method solves the problems that current common oral administration anti-phthisis western medicines are large in side effect and bad in medicine resistance and curative effect and injure the liver and kidneys. The method can be applied to the pneumology department to treat bronchitis, asthma, flu, sphagitis, rhinitis, nasosinusitis and other respiratory diseases besides the phthisis and pneumonia in the pulmonary medicine. The purple garlic liquid is a very good natural medicine, and the method is very good.
Owner:王星明

Chinese medicinal composition for treating chronic sinusitis

InactiveCN102327451AInhibition of secretionRestoring the cleaning function of ciliaRespiratory disorderPlant ingredientsAdjuvantBaical Skullcap Root
The invention belongs to the technical field of traditional Chinese medicines and discloses a Chinese medicinal composition for treating chronic sinusitis. The Chinese medicinal composition is prepared from the following raw material medicaments in part by weight: 25 to 35 parts of honeysuckle flower, 15 to 25 parts of biond magnolia flower, 10 to 20 parts of siberian cocklour fruit, 10 to 20 parts of angelica dahurica, 7 to 17 parts of baical skullcap root, 10 to 20 parts of Chinese thorowax root, 10 to 20 parts of gentian, 7 to 17 parts of rhizoma anemarrhenae, 15 to 25 parts of astragalus,5 to 15 parts of manchurian wildginger and 5 to 15 parts of liquoric root. The Chinese medicinal composition has the advantages that: chief medicaments, deputy medicaments, adjuvant medicaments and envoy medicaments have appropriate compatibility; the selected medicaments are excellent and combined; the Chinese medicinal composition has the effects of clearing heat and drying damp, diffusing and freeing the orifices, tonifying vitality and strengthening exterior, and strengthening body resistance and eliminating evil, can quickly remove sinus inflammation, restrain mucosal secretion and quickly eliminate clinical symptoms, has the effects of reconstructing damaged nasal mucosa and recovering the cleaning function of nasal mucosa cilia, consolidates the curative effect, does not have adverse effects after being taken for a long time, is safe to take, has an exact curative effect and is worth of clinical popularization.
Owner:陈群英

Traditional Chinese medicine for treating sinusitis

The invention relates to a traditional Chinese medicine for treating sinusitis. The traditional Chinese medicine is characterized by being prepared from the following active pharmaceutical ingredients in parts by weight: 12 parts of olibanum, 12 parts of myrrha, 16 parts of bulbus fritillariae thunbergii, 12 parts of radix curcumae, 10 parts of radix saposhnikoviae, 20 parts of rhizoma anemarrhenae, 10 parts of pericarpium citri reticulatae, 20 parts of radix astragali, 20 parts of cortex phyllodendri stirred with yellow rice wine, 10 parts of fructus forsythiae, 10 parts of platycodon grandiflorus, 8 parts of saussurea costus, 16 parts of semen pharbitidis, 10 parts of flos lonicerae and 6 parts of radix glycyrrhizae. Experiments prove that the traditional Chinese medicine can safely and effectively treat sinusitis.
Owner:解伟伟

Pharmaceutical combination of traditional Chinese medicines used for dispersing exterior pathogen, clearing heat and resolving dampness

The present invention discloses a pharmaceutical combination of traditional Chinese medicines used for dispersing exterior pathogen, clearing heat and resolving dampness, and a preparation method thereof. A dispersible tablet contains the following ingredients, by weight: 40 parts of agastache, and 60 parts of pig gall powder. The dispersible tablet of the present invention is a pure herbal pharmaceutical combination oral solid dosage form. The dispersible tablet of the invention is prepared based on compatibility principles of traditional Chinese medicine formulations, has the efficacies of resolving turbidity with aroma, relieving the stuffy nose, eliminating liver and gallbladder fire, and eliminating or easing nasal congestion caused by thick snivel and headaches, and can be used for sinusitis and rhinitis. The dispersible tablet of the present invention has advantages of small in dosage, convenient for taking, fast in absorption, high in bioavailability, portable, accurate in dosing, stable in quality, etc.
Owner:XIAN TAKOMED PHARMA TECH

Medicine for treating chronic sinusitis and preparation method thereof

The invention relates to a medicine for treating chronic sinusitis which is prepared by mixing leech, earthworm and plantain seed that are processed, flos magnoliae liliflorae, caulis akebiae, spica schizonepetae, honeysuckle, forsythia, radix scutellariae, golden cypress, anabaena, salvia miltiorrhiza, raw astragalus root, rehmanniae praeparatum, the root bark of the peony tree, ligusticum sinense oliver, bitter orange and liquorice; adding water into the mixture and decocting; merging decocted liquid; filtering and concentrating decocted liquid into clear paste, drying and grinding the clearpaste, and putting into capsules. The medicine has the effects of clearing away heat and toxic material, replenishing qi and invigorating the spleen, dispelling wind and eliminating dampness, and dissipating phlegm and promoting the restoration consciousness, so as to be used for treating chronic sinusitis with the total effective rate of 95.0%. The medicine also has the advantages of treating the symptoms and the root causes, high cure rate and no toxic side effect.
Owner:路正平

Low salt type lemon flavored salt soda water

The present invention relates to the field of salt soda water processing and specifically discloses low salt type lemon flavored salt soda water. In a preparation of the salt soda water, the following raw material ingredients are used: soft white sugar, a salicornia europaea extract, edible salt, edible essence, citric acids, an amino acid additive, sodium citrate, sorbitol, vitamins, carbon dioxide and the balanced being purified water. The edible salt is not singly used and the salicornia europaea extract is used to replace a part of sodium chloride, so that a problem that traditional salt soda water is bitter and salty, and does not quench thirsty is solved. The contained trace elements of calcium, potassium, magnesium, ferrum, iodine, etc., enzymes, fibers, alkaloid ingredients, etc. have significant effects on cancers, sinusitis, arthritis, high blood pressure, low blood pressure, low back pain, obesity, hemorrhoids, diabetes, thyroiditis, asthma and bronchitis and the salt soda water is in a low salt type and has a lemon flavor.
Owner:阜南椰枫食品有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products